What Is The Long-Term Forecast For The Global Metastatic Bone Disease Market Growing At 9.3% CAGR?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Are The Market Size Estimates For The Metastatic Bone Disease Market?
In recent times, the market size of the metastatic bone disease has substantially expanded. The growth will progress from $17.14 billion in 2024 and is estimated to reach $18.82 billion in 2025, growing at a compound annual growth rate (CAGR) of 9.8%. The increase during the previous period can be credited to factors like higher aging population, improved cancer awareness initiatives, upsurge in demand for potent pain management therapies, significant investment in discovering and developing drugs, and the prevalence of unhealthy lifestyles.
Anticipation of considerable expansion is predicted for the market of metastatic bone disease in the upcoming years. The forecasted increase will see the market value reach $26.82 billion in 2029, at a compound annual growth rate (CAGR) of 9.3%. The factors prompting this anticipated growth during the forecasted phase include a rising older population, an intensified focus on the innovation of new radiopharmaceutical medications, reimbursement policies, the generation of advanced treatments, an escalating demand for effective pain management treatments, and growing cognizance regarding metastatic bone disease. The forecast period’s prominent trends encompass technological advancements in diagnostic tools, enhanced diagnostic methods, innovations in treatment approaches, the application of artificial intelligence and machine learning algorithms, and technological evolutions in bone health management.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15859&type=smp
What Drivers Are Accelerating Expansion Of The Metastatic Bone Disease Market?
The surge in bone cancer instances is anticipated to fuel the expansion of the metastatic bone disease market. Bone cancer, a malignant tumor initiating in the bone cells, is escalating due to genetic factors, exposure to radiation and certain chemicals in the environment. Metastatic bone disease can develop from bone cancer, as the cancer cells from the primary tumor can disseminate through the blood or lymphatic system to form new tumors in other bones. For example, in 2023, the American Cancer Society, a non-profit organization based in the US, recorded 3,970 fresh cases of bone and joint cancer, a climb from the 3,910 cases registered in 2022. Consequently, the rising prevalence of bone cancer is steering the growth of the metastatic bone disease market.
What Are The Key Segment Trends Observed In The Metastatic Bone Disease Market?
The metastatic bone diseasemarket covered in this report is segmented –
1) By Treatment: Medication; Radiation Therapy; Surgical Intervention; Tumor Ablation Therapy
2) By Origin: Breast; Lung; Thyroid; Kidney; Prostate; Other Origins
3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
Subsegments:
1) By Medication: Bisphosphonates; Denosumab; Chemotherapy Drugs; Hormonal Therapies; Targeted Therapies; Radiation Therapy
2) By Radiation Therapy: External Beam Radiation Therapy; Internal Radiation Therapy
3) By Surgical Intervention: Bone Stabilization Surgery; Bone Resection Surgery; Spinal Decompression Surgery
4) By Tumor Ablation Therapy: Radiofrequency Ablation; Cryoablation; Microwave Ablation
Which Long-Term Trends Will Play A Crucial Role In The Metastatic Bone Disease Market?
Leading corporations in the metastatic bone disease market sector are focusing on the development of targeted therapies with an intention to enhance the results of the treatment. Targeted therapies function by specifically attacking cancerous cells in metastatic bone disease, thereby reducing harm to the healthy cells and delivering a personalized treatment base on the unique molecular aspect of each patient. As an example, in March 2022, Novartis AG, which is a pharmaceutical company based in Switzerland, launched Zometa (zoledronic acid). This bisphosphonate medication has been officially approved for the purpose of preventing skeletal-related incidents in patients suffering from bone metastases which stem from solid tumors and also multiple myeloma. These enhancements aim to better the treatment results and the patients’ quality of life who are dealing with metastatic bone disease.
Who Are The Major Stakeholders Operating In The Metastatic Bone Disease Market?
Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/metastatic-bone-disease-global-market-report
What Regional Factors Are Accelerating Growth In The Metastatic Bone Disease Market?
North America was the largest region in the metastatic bone disease market in 2024. The regions covered in the metastatic bone disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=15859&type=smp
Browse Through More Reports Similar to the Global Metastatic Bone Disease Market 2025, By The Business Research Company
Bone Growth Stimulator Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/bone-growth-stimulator-global-market-report
Bone And Joint Health Supplements Global Market Report 2025
Bone And Mineral Diagnostic Testing Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
